A5091666679- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Urologic and reproductive health conditions
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Head and Neck Cancer Studies
- Liver Disease Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Bone health and treatments
- Urological Disorders and Treatments
- Radiopharmaceutical Chemistry and Applications
- Urinary Bladder and Prostate Research
- Cancer Immunotherapy and Biomarkers
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Drug Transport and Resistance Mechanisms
- Hepatitis B Virus Studies
- Cancer Diagnosis and Treatment
- Biomarkers in Disease Mechanisms
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Lung Cancer Treatments and Mutations
Aga Khan University Hospital
2007-2024
German Cancer Research Center
2021-2024
Heidelberg University
2021-2024
Cancer Research UK Manchester Institute
2017-2023
University of Manchester
2017-2023
DKFZ-ZMBH Alliance
2023
National Center for Tumor Diseases
2023
University Hospital Heidelberg
2023
Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology
2022
Prostate Cancer Research
2019-2022
BackgroundBased on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic cancer, and benefit be greatest patients a low burden. We aimed compare standard of care for without radiotherapy.MethodsWe did randomised controlled phase 3 trial at 117 hospitals Switzerland UK. Eligible had newly diagnosed cancer. randomly allocated open-label 1:1 ratio (control group) or (radiotherapy group). Randomisation was stratified by...
Background STAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed cancer low metastatic burden, but not those high-burden disease. In this final analysis, we report long-term findings on primary outcome measure of OS and secondary measures symptomatic local events, RT toxicity quality life (QoL). Methods Patients were randomised at care sites in United Kingdom Switzerland between January 2013 September 2016,...
The role and molecular mechanisms of intermittent fasting (IF) in non-alcoholic steatohepatitis (NASH) its transition to hepatocellular carcinoma (HCC) are unknown. Here, we identified that an IF 5:2 regimen prevents NASH development as well ameliorates established fibrosis without affecting total calorie intake. Furthermore, the blunted NASH-HCC when applied therapeutically. timing, length, number cycles type diet were critical parameters determining benefits fasting. Combined proteome,...
Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of burden criteria, it is not clear how this benefit varies bone metastasis counts and site.
Abstract Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial men starting long‐term hormone therapy for prostate cancer. This analysis metastatic patients was planned 3 years after the first results. Standard‐of‐care (SOC) androgen deprivation therapy. The comparison randomised 1:1 to SOC‐alone with or without daily abiraterone 1000 mg + 5 (SOC AAP), continued until disease progression. primary outcome...
The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling analyze the molecular heterogeneity in basal luminal compartments. Within compartment, we identify a subset intrinsically resistant castration with bi-lineage expression pattern. discover LY6D as marker progenitors multipotent differentiation enriched organoid-forming capacity. Lineage tracing further reveals that LY6D+ can produce LY6D− cells....
Class III β-tubulin (βIII-tubulin) is expressed in tissues of neuronal lineage and also several human malignancies, including non-small-cell lung carcinoma, breast ovarian cancer. Overexpression βIII-tubulin these tumours associated with an unfavourable outcome resistance to taxane-based therapies. At present, expression remains largely uncharacterised prostate In this report, we evaluated the 138 different tumour specimens by immunohistochemistry from patients hormone-treated or...
Abstract Prostate cancer (PCa) is the fifth leading cause of related deaths worldwide, in part due to a lack molecular stratification tools that can distinguish primary tumours will remain indolent from those metastasise. Amongst potential biomarkers, microRNAs (miRs) have attracted particular interest because their high stability body fluids and fixed tissues. These small non-coding RNAs modulate several physiological pathological processes, including progression. Herein we explore...
Abstract Introduction The Hippo pathway and its transcriptional effectors yes-associated protein (YAP) coactivator with PDZ-binding motif (TAZ) are targets for cancer therapy. It is important to determine if the activation of one factor compensates inhibition other. Moreover, it unknown YAP/TAZ-directed perturbation affects cell–cell communication non-malignant liver cells. Materials Methods To investigate liver-specific phenotypes caused by YAP TAZ inactivation, we generated mice hepatocyte...
Varicella and herpes zoster are two distinct clinical diseases caused by the herpesvirus varicella-zoster virus (VZV). is a contagious exanthem that typically occurs in children presents with scattered lesions. It more severe adults immunocompromised persons, potentially fatal outcomes. Live attenuated Oka VZV vaccinations have eradicated varicella, whereas Herpes painful, rash-like illness chronic neuropathic pain. Therapeutic alternatives include antiviral medication, analgesics,...
Prostate cancer is typically asymptomatic and usually diagnosed through concerted screening programs. However, in settings where there are no existing national prostate programs, it may be picked up at the clinics patients presenting with urinary symptoms, erectile dysfunction, hematospermia/hematuria. Rare atypical presentations also occur, delaying diagnosis management. This case report discusses a 61-year-old male of Black-African descent, whose first presentation to hospital for...
Human papillomavirus (HPV) is recognized as a major causative agent for cervical carcinomas. Based on their oncogenic potential, HPV subtypes have been divided into high- and low-risk. In Pakistan, screening in female patients not commonly practiced, consequence, the degree of prevalence its correlation with cancer unknown.In this study, we attempted to estimate infection, also subtype profile, among Pakistani women from varied geographical, racial, social backgrounds within Pakistan.Women...
The prostate cancer (PCa) diagnostic pathway is undergoing a radical change with the introduction of multiparametric magnetic resonance imaging (mpMRI), genomic testing, and different biopsy techniques. It has been proposed that these tests should be used in sequential manner to optimise risk stratification.
The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and prevalence baseline genomic aberrations, we sequenced tumor germline DNA from patients metastatic cancer (mPCa) starting long-term androgen-deprivation therapy (ADT).
Oral squamous cell carcinoma (OSCC) is a top-ranked cancer in the Pakistani population, and patient survival has remained unchanged at ∼50% for several decades. Recent advances have claimed that subset of tumour cells, called stem cells (CSCs), are responsible progression, treatment resistance, metastasis, which leads to poor prognosis. This study investigated impact CSC markers expression on overall (OS) disease-free (DFS) OSCC patients. Materials Methods. Immunohistochemistry was used...
Metastatic and high-risk localized prostate cancer respond to hormone therapy but outcomes vary. Following a pre-specified statistical plan, we used Cox models adjusted for clinical variables test associations with survival of multi-gene expression-based classifiers from 781 patients randomized androgen deprivation or without abiraterone in the STAMPEDE trial. Decipher score was strongly prognostic (p<2×10-5) identified clinically-relevant differences absolute benefit, especially cancers. In...
Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication change advanced cancer, which defines a wide spectrum disease from high-risk localised to metastatic, is unknown.
To determine the prognostic relevance of non-regional lymph node (NRLN) metastases presenting synchronously with bone in metastatic prostate cancer (mPCa) for guiding treatment decisions based on oligometastatic definitions.Patients diagnosed mPCa between 2004 and 2013 were identified from Surveillance, Epidemiology End Results database grouped by sites into only NRLN, bone, + NRLN other ± bone/NRLN metastases. Multivariate Cox competing risk regression analyses performed to compare risks...
Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state based on manual bone metastasis counts, but enumeration of metastases limited by interobserver variations, and it does not account volume or lesional coalescence. automated scan index (aBSI) quantitative method evaluating burden in standardised reproducible manner.To evaluate whether aBSI has utility as predictive imaging...